Who are continuous infusion of 5-fluorouracil's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Xeloda, Fudr, Folic Acid, 5-fluoro-uracil, Irinotecan, 5FU, leucovorin, chemotherapy of mFOLFOX6 or FOLFIRI.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/continuous-infusion-of-5-fluorouracil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

continuous infusion of 5-fluorouracil — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

continuous infusion of 5-fluorouracil (continuous infusion of 5-fluorouracil) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: pyrimidine analog. Area: Oncology.

phase 3 pyrimidine analog thymidylate synthase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

continuous infusion of 5-fluorouracil (continuous infusion of 5-fluorouracil) — Japan Clinical Oncology Group. 5-fluorouracil is a thymidylate synthase inhibitor that disrupts DNA synthesis and function.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
continuous infusion of 5-fluorouracil TARGET	continuous infusion of 5-fluorouracil	Japan Clinical Oncology Group	phase 3	pyrimidine analog	thymidylate synthase
Xeloda	capecitabine	Cheplapharm	marketed	Nucleoside Metabolic Inhibitor [EPC]	Thymidylate synthase	1998-01-01
Fudr	FLOXURIDINE		marketed	Antimetabolite [EPC]	Thymidylate synthase	1970-01-01
Folic Acid	FOLIC ACID	Pfizer	marketed	Vitamin C [EPC]	Thymidylate synthase	1946-01-01
5-fluoro-uracil	5-fluoro-uracil	UNICANCER	marketed	Antimetabolite	Thymidylate synthase; RNA and DNA incorporation
Irinotecan, 5FU, leucovorin	Irinotecan, 5FU, leucovorin	Asan Medical Center	marketed	Chemotherapy combination (topoisomerase I inhibitor + antimetabolite)	Topoisomerase I; thymidylate synthase
chemotherapy of mFOLFOX6 or FOLFIRI	chemotherapy of mFOLFOX6 or FOLFIRI	Xu jianmin	marketed	Combination chemotherapy regimen	Thymidylate synthase (5-FU), DNA topoisomerase I (irinotecan), DNA (oxaliplatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (pyrimidine analog class)

AstraZeneca · 1 drug in this class
China Medical University, China · 1 drug in this class
Grupo Espanol de Tumores Neuroendocrinos · 1 drug in this class
Japan Clinical Oncology Group · 1 drug in this class
Servicio de Salud Metropolitano Sur Oriente · 1 drug in this class
UNICANCER · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). continuous infusion of 5-fluorouracil — Competitive Intelligence Brief. https://druglandscape.com/ci/continuous-infusion-of-5-fluorouracil. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab